Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02972580 · ClinicalTrials.gov registry record
Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD
A clinical trial of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy, sponsored by Nationwide Children's Hospital.
- Active
- Registry status
- 250
- Enrollment target
- 1
- Study location
NCT02972580 is a study of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy that is active but no longer recruiting, run by Nationwide Children's Hospital. The registered enrollment target is 250 participants, below the 407-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02972580, a study of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy, is active but no longer recruiting, sponsored by Nationwide Children's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
Longitudinal prospective observational study. This is a 24-month study with the possibility of extending the data time points. Initially baseline, then 12 and 24 months follow up studies will be completed.
Conditions Studied
Interventions
- GENETIC Genetic characterization
Study Locations (1)
Ohio
- Nationwide Children's Hosptial - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2016-06 |
| Est. Completion | 2030-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02972580
The ClinicalTrials.gov registry entry for NCT02972580 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 407-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (39% lower). The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which Genetic characterization is the first listed.
NCT02972580 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02972580 about?
NCT02972580 is a clinical study titled "Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD". Longitudinal prospective observational study. This is a 24-month study with the possibility of extending the data time points. Initially baseline, then 12 and 24 months follow up studies will be completed.
What is the current status of trial NCT02972580?
This trial is currently active not recruiting. The enrollment target is 250 participants. The study started on 2016-06. Estimated completion is 2030-12.
What conditions does trial NCT02972580 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy.
What interventions are being tested in trial NCT02972580?
The interventions under investigation include: Genetic characterization (GENETIC).
Who is sponsoring clinical trial NCT02972580?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02972580 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Once Weekly Infant Corticosteroid Trial for DMD
RECRUITING · Phase 4
-
The Duchenne Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.